DOI: 10.1001/jamanetworkopen.2026.29936 ISSN: 2574-3805

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer

Murilo A. Luz, Alberto Briganti, Declan G. Murphy, Christopher M. Pieczonka, Hiroyoshi Suzuki, Evan Y. Yu, Xavier Artignan, Geoffrey T. Gotto, Joelle P. Hamilton, Ryan J. Malone, Patrick Adorjan, Mercedeh Ghadessi, Frank Verholen, Andrew J. Armstrong
Show PDF Cite

This nonrandomized clinical trial assesses the safety and efficacy of darolutamide, with or without concomitant lipid-modifying agents (LMAs), in treating nonmetastatic castration-resistant prostate cancer.

More from our Archive